Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
Dow rebounds over 500 points in final hour of trade as Treasury and UK government bond yields fall after BOE intervention
07:09pm, Wednesday, 28'th Sep 2022 MarketWatch
U.S. stock indexes on Wednesday turned higher, helped by a fall in Treasury yields and a surprise intervention from the Bank of England in the U.K. gilt market, but Wall Street stocks were still in da
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success
06:45am, Wednesday, 28'th Sep 2022 MarketWatch
Biogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Change in the Roche Board of Directors
05:25am, Monday, 26'th Sep 2022 GlobeNewswire Inc.
Basel, 26 September 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Julie Brown has notified the Board that she will step down as a member of the Roche Board of Directors as she has acc
Roche’s vision-loss drug Vabysmo gets EU nod
06:01am, Monday, 19'th Sep 2022 MarketWatch
The approval from the European Commission--the EU's executive arm--comes after four phase-3 studies showing vision gains and anatomical improvements in patients given the drug, Roche said.
European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
05:00am, Monday, 19'th Sep 2022 GlobeNewswire Inc.
Basel, 19 September 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) for the treatment of neovascular or ‘wet’ age-related
Should You Invest in the Invesco S&P SmallCap Information Technology ETF (PSCT)?
10:20am, Tuesday, 13'th Sep 2022 Zacks Investment Research
Sector ETF report for PSCT
Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases
05:00am, Tuesday, 23'rd Aug 2022 GlobeNewswire Inc.
Basel, 23 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Digital LightCyclerⓇ System, Roche’s first digital polymerase chain reaction ( PCR) system. This next-g
FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
05:00am, Tuesday, 16'th Aug 2022 GlobeNewswire Inc.
Basel, 16 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBL
Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2
05:00am, Monday, 15'th Aug 2022 GlobeNewswire Inc.
Basel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supp
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
05:00am, Friday, 12'th Aug 2022 GlobeNewswire Inc.
Basel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for
Rogers Corp. (ROG) Misses Q2 Earnings Estimates
12:25am, Thursday, 04'th Aug 2022 Zacks Investment Research
Rogers Corp. (ROG) delivered earnings and revenue surprises of -14.69% and 0.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Stoneridge (SRI) Reports Q2 Loss, Tops Revenue Estimates
11:55pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Stoneridge (SRI) delivered earnings and revenue surprises of -38.10% and 7.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rogers Corp. (ROG) Misses Q2 Earnings Estimates
09:49pm, Wednesday, 03'rd Aug 2022
Rogers Corp. (ROG) delivered earnings and revenue surprises of -14.69% and 0.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results
05:00am, Tuesday, 02'nd Aug 2022 GlobeNewswire Inc.
Basel, 2 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endp
Roche to present scientific progress across Alzheimer’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting
05:00am, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
Basel, 28 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 41 abstracts across its portfolio of Alzheimer’s disease pharmaceuticals and diagnostics will be presented at
